Barco announces the arrival of its skin imaging solution growth initiative Demetra to the US market

Barco announces the arrival of its skin imaging solution growth initiative Demetra to the US market Atlanta, Georgia, 3 November 2020 - Today, Barco announces that its revolutionary skin imaging platform, Demetra, is available in the U.S. market.

A proven leader in healthcare innovation, Barco once again demonstrates the company's commitment to providing best-in-class medical solutions with the launch of Demetra. With Demetra, medical professionals now have access to a state-of-the-art tool that will allow for dermoscopic, close-up and overview images with intelligent insights. This will support in the diagnosis of skin cancer and the ability to track changes in skin lesions over time. For the patient, studies indicate that early detection of cancer results in more effective treatment and higher survival rates.

Demetra is a clear example of Barco's mission of enabling bright outcomes. In the United States, current estimates are that one in five Americans will be diagnosed with skin cancer in their lifetimei. As health systems in the US move to more preventative models of care, providing advanced diagnostic technology at the point of care will become increasingly important, states Jan De Witte, CEO of Barco.

Co-developed with leading dermatologists, the award-winning Demetra-solution combines innovative technology with a unique design that allows dermatologists to take dermoscopic as well as clinical images, making mapping and skin lesion follow-up fast and easy. The solution integrates and blends advanced hardware and software technology and is offered to dermatologists as a service with a monthly fee payment structure.

The adoption of digital platforms, like Demetra, provides medical professionals access to best-in-class solutions that help provide accurate diagnoses. The solution is now ready to expand coverage to the US, a key market for Demetra, following its first commercial test phase in Belgium and Germany and FDA-clearance granted in December 2019ii. In parallel to the commercial launch in the US, the Demetra team also continues to investigate, develop and validate further workflow improvements, as well as innovative AI-functionalities to support clinical decisions in real time. Some of these novel technologies are already in final clinical trial stage. As our community of experts grow, so will the power of the platform.

Demetra has been developed with innovative clinicians and scientists over several years and is now poised to disrupt the US Dermatology market. We are excited to bring these new technologies to support clinicians' ability to improve the efficiency of patient care and deliver better outcomes in the fight against skin cancer, states Peter Kinhan, Vice President of Demetra.

To learn more about Demetra and arrange for a demonstration, please visit www.barco.com/demetra.

About Barco

Barco designs technology to enable bright outcomes around the world. Seeing beyond the image, we develop visualization and collaboration solutions to help you work together, share insights, and wow audiences. Our focus is on three core markets: Enterprise (from meeting, classroom and control rooms to corporate spaces), Healthcare (from the radiology department to the operating room), and Entertainment (from movie theaters to live events and attractions). In 2018, we realized sales of 1.028 billion euro. We have a global team of 3,600 employees, whose passion for technology is captured in 400 granted patents.

For more information, visit us at www.barco.com, follow us on Twitter (@Barco), LinkedIn (Barco), YouTube (BarcoTV), or like us on Facebook (Barco).

Copyright 2019 by Barco

i https://www.aad.org/media/stats-skin-cancer

ii Additional features are currently pending FDA clearance.

LINK:	https://www.barco.com/en/News/Press-releases/Barco-announces-the-arriv...
	See more stories from projectdesign

Most recent headlines